Odyssey Therapeutics (ODTX) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($920.8 million vs $674.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ODTX | PROK |
|---|---|---|
| Share price | $19.16 | $1.69 |
| Market cap | $920.80M | $674.62M |
| 1-day change | +5.74% | +1.80% |
| YTD return | — | -25.89% |
| 1-year return | — | -49.08% |
| 5-year return | — | -83.18% |
| EPS (TTM) | $-7.55 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.05 | $3.48 |
| 52-week low | $15.10 | $1.30 |
| Distance from 52-week high | -34.04% | -51.44% |
| Analyst consensus | none | none |
| Avg. price target upside | +86.59% | +269.82% |
| Average volume | 274.77K | 1.30M |
| Shares outstanding | 48.06M | 208.93M |
| Employees | 100 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
ODTX vs PROK FAQ
Which is bigger, Odyssey Therapeutics or ProKidney?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $920.80M compared with $674.62M for ProKidney (PROK).
Are Odyssey Therapeutics and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.